Melphalan
- PDF / 151,522 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 44 Downloads / 158 Views
1 S
Cystoid macular oedema: 2 case reports In a case report, two patients including a 1-year-old boy and a 4-year-old girl were described, who developed cystoid macular oedema (CME) following treatment with melphalan for bilateral retinoblastoma. Case 1: A 1-year-old boy presented with bilateral retinoblastoma. He underwent left eye enucleation and received six cycles of carboplatin, etoposide and vincristine (CEV) systemic chemotherapy and two cycles of intra-arterial melphalan. Six months later, a vitreous relapse on his right eye was noted. Then, he received intravitreal melphalan injection 30µg three weekly. Three weeks after the completion of intravitreal melphalan, the visual acuity dropped from 20/32 to 20/125. The tumour was under control. A macular optical coherence tomography (OCT) revealed CME. He was treated with prednisolone, which improved the visual acuity with resolution of the CME. The CME recurred after 2 months, which responded to unspecified topical NSAIDs. During follow-up after 2 years, visual acuity was found to be stable. Case 2: The girl presented at the age of 2-years with bilateral retinoblastoma. She underwent left eye enucleation and received six cycles of carboplatin, etoposide and vincristine (CEV) systemic chemotherapy, along with focal therapy for the right eye. After two years, a localised vitreous recurred, which partially responded to iodine-125 brachytherapy. She also received intravitreal melphalan injection 20µg three weekly. One month after the last dose of intravitreal melphalan, she developed CME. She waas treated with unspecified NSAIDs, acetazolamide and sub-tenon triamcinolone. Over 6 months, the CME resolved. Panthagani J, et al. Cystoid macular edema following intravitreal chemotherapy treatment for retinoblastoma. Pediatric Blood and Cancer 67: e28348, No. 9, Sep 2020. 803501619 Available from: URL: http://doi.org/10.1002/pbc.28348
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
